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Abstract
Migraine is a highly prevalent neurological disorder
imparting a major burden on health care around the
world. The primary pathology may be a state of
hyperresponsiveness of the nervous system, but the
molecular mechanisms are yet to be fully elucidated.
We could now be at a watershed moment in this
respect, as the genetic loci associated with typical
forms of migraine are being revealed. The genetic
discoveries are the latest step in the evolution of our
understanding of migraine, which was initially
considered a cerebrovascular condition, then a
neuroinflammatory process and now primarily a
neurogenic disorder. Indeed, the genetic findings,
which have revealed ion channels and transporter
mutations as causative of migraine, are a powerful
argument for the neurogenic basis of migraine.
Modulations of ion channels leading to amelioration
of the migraine ‘hyperresponsive’ brain represent
attractive targets for drug discovery. There lies ahead
an exciting and rapidly progressing phase of migraine
translational research, and in this review we highlight
recent genetic findings and consider how these may
affect the future of migraine neurobiology and
therapy.
Introduction
Migraine is a common, episodic neurological disorder
characterised by severe headaches, and in about one-
third of cases it is preceded by a focal, transient neuro-
logical phenomenon termed the ‘aura’.W h e t h e r
migraine with aura (MA) and migraine without aura
(MO) are distinct or overlapping entities is somewhat
contested, but it is not uncommon for patients to
experience both forms of migraine. Migraine affects up
to 18% of women and 6% of men, with a peak incidence
between 25 and 55 years of age [1]. The disease has
long fascinated clinicians and scientists, with
descriptions of migraine-like symptoms appearing in
antiquity; however, only recently have the pathogenic
mechanisms started to be unravelled. This is particularly
true for MA, which is perhaps a more homogeneous
and tractable condition for study than MO, because the
phenotype of MA is well defined and genetics likely play
a greater role [2].
The migraine aura is likely caused by ‘cortical spread-
ing depression’ (CSD), a wave of intense neuronal and
glial depolarization followed by a period of inactivity,
slowly progressing over the cortex [3,4]. The trigeminal
system (TGVS), consisting of the meningeal and superfi-
cial cortical blood vessels that are innervated by the tri-
geminal nerve, is strongly implicated in the initiation of
the headache pain [5]. The TGVS projects to the tri-
geminal nucleus caudalis (TNC) in the brainstem, which
in turn projects to higher-order pain centres. Animal
models provide evidence that CSD could be linked to
activation of the TGVS, thus providing a hypothetical
triggering mechanism for the migraine headache [6].
However, such a link in the human brain is still contro-
versial [7], and although silent CSD has been speculated
to be a cause, the relationship of CSD and MO is
uncertain.
In this review, we consider the emerging genetic dis-
coveries about migraine, beginning with familial hemi-
plegic migraine, where the search for causative genes
has been particularly rewarding. The more typical forms
of migraine have been considerably more challenging,
but we describe the exciting discoveries of the past year.
T h ed i s c o v e r yo far o l ef o rt h eT W I K - r e l a t e ds p i n a l
cord potassium channel (TRESK) in migraine, in parti-
cular resurrects the debate over the relative importance
of peripheral and central mechanisms in migraine pain,
and the origin of the headache is therefore considered.
We next highlight the growing importance of glial cells
in migraine pathogenesis, as evidenced by the expression
pattern of migraine-causative genes, and finally we
describe potential directions for migraine treatment.
Familial hemiplegic migraine
Genetic factors are clearly involved in the aetiology of
migraine, as illustrated by twin studies [8]. Complex
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inheritance pattern [9], revealing the multigenic nature
of migraine. Often a profitable approach to studying
such complex genetic diseases is to interrogate an auto-
somal dominant subtype of the condition. Familial
hemiplegic migraine (FHM) is a rare, monogenic sub-
type of MA [10]. Clinically, FHM patients experience a
headache phase similar to that experienced by common
migraineurs, but FHM is distinguished by additional
prolonged hemiparesis. To date, three genes, when dis-
rupted, have been identified as causing FHM: CACNA1A
(FHM1) [11], encoding the a1 subunit of neuronal
Cav2.1 Ca
2+ channels; ATP1A2 (FHM2) [12], encoding
the a2s u b u n i to fN a
+/K
+ ATPase pumps; and SCNA1
(FHM3) [13], encoding the pore-forming a1 subunit of
neuronal Nav1.1 Na
+ channels. More recently, a muta-
tion in SLC4A4 [14] encoding the Na
+-HCO3
- cotran-
sporter NBCe1 has been identified in sisters with FHM,
and a mutation in SLC1A3 [15] encoding the glial
glutamate transporter EAAT1 has been identified in one
patient with pure hemiplegic migraine.
The common thread between these genes adds weight
to the notion that FHM (and hence potentially common
migraine) is essentially a channelopathy [16] (Figure 1).
Cellular and knockin mouse models of FHM1 have pro-
vided evidence for a gain-of-function effect of CAC-
NA1A mutations on channel function [11,17]. Cav2.1
channels are expressed presynaptically by neurons and
couple depolarisation of the membrane with neurotrans-
mitter release [18]; thus a channel ‘gain-of-function’
would predict increased neurotransmission [19]. A more
complex spectrum of Nav1.1 defects, including loss and
gain of function, can cause FHM3 [20]. Data derived
from a Nav1.1-knockout mouse model show that a loss
of one allele predominantly decreased activity of
GABAergic inhibitory interneurons whilst having no
effects on excitatory pyramidal neurons [21]. In contrast,
mice with overexpression of a gain-of-function Nav1.2
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Figure 1 Migraine mutations affecting the central glutamate synapse. Increased Ca2+ influx caused by familial hemiplegic migraine
subtype 1 (FHM1) associated mutations in Cav2.1 channels enhance glutamate release from presynaptic terminals. Loss of Na+/K+ ATPase
function, as seen in FHM2, indirectly reduces astrocyte uptake of glutamate, resulting in increased levels of the neurotransmitter in the synaptic
cleft. FHM3 associated mutations can reduce firing of inhibitory interneurons or potentiate presynaptic action potential generation. Mutations in
SLC4A4 inhibit glia-mediated acid secretion and thus free N-methyl-D-aspartate (NMDA) receptors from proton-mediated inhibition. Activity of
EAAT1, the major glutamate transporter in the brain, is directly affected by a mutation in its sequence and indirectly by upregulation of MTDH,a
likely consequence of a reported mutation in rs1835740. LRP1 has a role in glutamate signalling and has been shown to directly modulate
NMDA-dependent calcium currents in vitro.
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activated excitatory hippocampal pyramidal neurons
[22]. These findings demonstrate well that the final
effect on central nervous system (CNS) excitability is
very dependent on whether the predominant effect of a
mutation is on inhibitory or excitatory neurons. The
importance of glia is evident in FHM2, and all studied
mutations yield a ‘loss-of-function’ of the Na
+/K
+
ATPase pump [23]. These pumps are essential for the
uptake and clearance of neurotransmitters and K
+ ions
from the synaptic cleft by astrocytes, so loss of function
mutations could result in an increase in extracellular
neurotransmitter and K
+ levels. Neuronal excitation
causes extracellular alkalosis, but this is buffered by acid
secretion from glial cells. Such secretion is induced by
glial cell depolarization and mediated by inward rectify-
ing Na
+ HCO3
- cotransport [24]. Mutations in SLC4A4,
another glial transporter that has been reported to cause
FHM in two sisters, cause defective trafficking of
NBCe1 and reduced intracellular alkalization in C6
glioma cells [14]. Decreased capacities to buffer extracel-
lular alkalosis could result in increased neuronal excit-
ability, as N-methyl-D-aspartate (NMDA) receptors are
sensitive to inhibition by protons [24].
While FHM and migraine overlap significantly, pheno-
typic differences do exist [25]. Despite this, FHM serves
as a highly valuable model of migraine. The usefulness
of FHM genetic studies extends beyond simply identify-
ing genes responsible for rare migraine subtypes. More
importantly, they have provided mechanistic insights
into the pathobiology of migraine in general, which
seems likely to be a disease related to ionic disturbances
with a resultant altered excitability of certain areas of
the brain. Adopting this hypothesis may help prioritize
findings among the large volume of data arising from
genome-wide association studies and genome sequen-
cing by examining ionic homeostasis pathways.
Migraine
Although multiple genes have been implicated in FHM,
evidence for genetic alterations associated with common
forms of migraine had been lacking. There have been
numerous linkage studies, and despite some replication,
the genetic abnormalities at these loci remain unknown
[26,27]. Very many association studies of candidate
genes have also been undertaken but have been ham-
pered by the relatively small sample sizes. Since 2010,
several genetic loci have been identified in association
with ‘typical’ migraine. The first was found in a large,
genome-wide association study comprising 2,731 MA
patients at three separate European headache clinics.
The minor allele of rs1835740 on chromosome 8q22.1
was shown to be linked to migraine with and without
aura [28]. Two genes, MTDH and PGCP,f l a n kt h e
region. More functional work is needed to determine
the relevance of such polymorphisms to MTDH and
PGCP gene expression; however, it is interesting to note
that both genes have a role in regulating levels of extra-
cellular glutamate in the brain, a neurotransmitter heav-
ily implicated in migraine pathogenesis [29]. A second
study published in 2011 identified three additional sus-
ceptibility loci for common migraine [30]. The three
SNPs mapped within or near transcribed regions of
known genes: LRP1, PRDM16 and TRPM8. LRP1 is
highly expressed by neurons and is found in association
with NMDA receptors in dendritic synapses [31] linking
the SNP with disrupted central glutamate signalling.
While the plausible link between PRDM16 and migraine
is not obvious, the association of TRPM8 is intriguing.
The gene encodes for a sensor of cold and cold-induced
burning pain, which is primarily expressed in sensory
neurons such as the trigeminal ganglion and the dorsal
root ganglion [32]. TRPM8 is considered to have a role
in animal models of neuropathic pain [33], a disorder
that shares some similarities with migraine [34].
The genome-wide association studies in migraine have
yielded plausible susceptibility loci, but further work is
still required to confirm that the identified SNPs are
causally related and the adjacent genes are relevant to
migraine. An alternative approach that can yield more
immediate insights into disease pathogenesis is family-
based genetic studies. A candidate gene approach fol-
lowed up by linkage and functional analysis revealed a
mutation in KCNK18, the gene encoding TRESK, that
segregated with MA in a large pedigree. TRESK is a
member of the two-pore potassium channel family
showing neuronal expression [35]. KCNK18 was chosen
for screening, as the channel was known to play a pro-
minent role in neuronal excitability and therefore was
postulated to participate in pain pathways [36]. Further-
more, volatile anaesthetics such as halothane have been
shown to activate TRESK and are known to inhibit CSD
[37]. One migraine proband was identified as carrying a
two-bp deletion in the KCNK18 gene, which leads to
premature truncation of the protein. The frameshift
mutation F139WfsX24 was found to cosegregate per-
fectly with the migraine phenotype in relatives of the
proband. Patch-clamp recordings from Xenopus oocytes
revealed a loss of protein function and a dominant-
negative action of mutant subunits on wild-type TRESK
channels. Further work confirmed that TRESK is
expressed in migraine-salient areas such as the trigem-
inal ganglion, the cortex and the dorsal root ganglion
[38]. In a mouse knockout model, loss of TRESK results
in a 20% increase in sensitivity to thermal pain [39]. It is
expected that a loss of K
+ leak current would lead to the
reduced rheobase current required for neuronal spiking,
as shown in dorsal root ganglion neurons of TRESK
-/-
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one large family, and therefore further studies are
required to confirm any broader role in migraine patho-
genesis. Nevertheless, given the strong expression and
physiological function of TRESK in trigeminal ganglia
and the central role of the trigeminal ganglia in
migraine, modulation of TRESK is a viable target for
migraine therapy. Furthermore, the protein has no close
paralogues, and known compounds have already been
shown to influence channel activity [21].
Origin of the headache
While CSD is largely accepted as the neurophysiological
correlate of the aura, the cause of the headache phase of
migraine is less established and there is considerable
debate whether the pain is peripheral or central in origin.
Early observations by Harold Wolff [41] that the superfi-
cial temporal artery becomes dilated during migraine and
that electrical stimulation of dural and cerebral arteries
results in nausea and the perception of pain strikingly
similar to that in migraine [42] led to the idea that the vas-
culature has a role to play in headache initiation. Whilst
cerebral blood flow changes are clearly not the primary
pathology in migraine, the trigeminovascular system is still
considered by many to be the essential substrate of
migraine pain (Figure 2). Indeed, in rodents, CSD has
been shown to cause activation of the trigeminovascular
system along with dilatation of the middle meningeal
artery, both of which are abolished by ipsilateral trigeminal
denervation [6]. Proponents of an intrinsic CNS mechan-
ism point instead to dysfunction of the brainstem as the
principal source of the headache. Neuromodulatory struc-
tures such as the periaqueductal gray (PAG), the locus
coeruleus (LC) and the raphe nuclei (RN) modulate
responses to afferent traffic [5]. Positron emission tomo-
graphy has revealed activation of such areas of the brain-
stem during acute attacks. Additionally electrical
stimulation of the PAG can induce migraine-like headache
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Figure 2 Neuronal circuitry in migraine pain generation. Cortical spreading depression (CSD) triggers plasma protein extravasation from
dural blood vessels, which in turn activates trigeminal (TG) afferents. Multiple mutations have been found in familial and sporadic migraine that
could reduce the threshold for firing of TG neurons, either directly by affecting neuronal excitability or indirectly by modulating local glia activity.
Signals are transduced to the trigeminal nucleus caudalis (TNC), which receives several modulatory inputs from other areas of the brainstem,
such as the periaqueductal gray (PAG), the locus coeruleus (LC) and the raphe nuclei (RN). These areas have been proposed as sites of
dysfunction in migraine. The TNC projects to rostral brain areas, where the perception of pain is generated.
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eral structures in migraine headache will become apparent
as the expression pattern of migraine genes is character-
ized. For example, the identification of KCNK18 and
TRPM8 as migraine-associated genes, both highly
expressed in sensory neurons, would certainly support the
importance of peripheral neurons. This in turn has impli-
cations for drug design and delivery, since blood-brain
barrier permeability may not be a prerequisite for a
migraine headache therapeutic drug.
Neuron and glia interactions
T h em u l t i g e n i cn a t u r eo fm i g r a i n el e n d si t s e l ft ot h e
idea that multiple perturbations in homeostasis are
required for disease pathology. Evidence derived from
FHM mutations points to an important role of astro-
cytes in migraine. During late gestation and the early
neonatal stage, ATP1A2 is expressed predominantly in
neurons; however, by adulthood, the gene is expressed
primarily in astrocytes. This expression switch may
explain the clinical phenotype switch seen in patients.
Young FHM2 patients often have infantile epilepsy (pre-
sumably as a consequence of neuronal hyperexcitability),
whereas by adulthood the symptoms are more of the
classical FHM2 type, that is, migraine attacks caused by
impaired neurotransmitter uptake by astrocytes [44].
Astrocytes are critical in modulating the neuronal
microenvironment, as they control extracellular ionic
composition and prevent accumulation of neurotrans-
mitters in the synaptic cleft [45]. Spinal glial activation
h a sb e e ns u g g e s t e dt op l a yar o l ei nav a r i e t yo fp a i n
states [46]. Intracellular Ca
2+ oscillation in cultured
astrocytes
shows significant similarity to CSD [47] and has been
suggested to contribute to the propagation of spreading
depression [48]. However, the role of glial calcium
waves in vivo, where intracellular Ca
2+ oscillation has yet
to be robustly shown, is contested [49]. The release of
proinflammatory mediators by glia may also contribute
to central sensitisation of migraine and to the develop-
ment of symptoms such as allodynia [32,50]. Chronic
opioid treatment can result in hyperalgesia and allody-
nia, potentially by activating glial cells [51], whilst
administration of naloxone, which blocks microglial acti-
vation, enhances the analgesic effect of morphine [52].
It is therefore becoming increasingly clear that glia
have a role beyond simply myelination and maintaining
neuronal homeostasis. They appear to directly and
actively influence the excitability of neurons and as such
may represent a novel means of modulating neuronal
activity and responsiveness.
Migraine therapy
Therapies are broadly divided into acute symptomatic
and prophylactic. To date, triptans are the gold standard
in acute migraine therapy. They are potent 5-hydroxy-
tryptamine (serotonin) subtypes 1B and 1D receptor
agonists that, when delivered orally, are effective in 29%
to 64% of patients, depending on the criteria used to
define pain relief: (1) pain-free after two hours and (2)
moderate or severe pain to mild or no pain after two
hours, respectively [53,54]. However, clinical use can be
limited by their potent vasoconstriction [55]. The most
significant recent advance in acute treatments relates to
calcitonin gene-related peptide (CGRP) receptor antago-
nists. Stimulation of TG neurons results in the release
of CGRP [56]; high levels of CGRP are found in external
jugular venous blood during migraine attacks [57]; and
infusion of CGRP can cause MO [58]. Telcagepant (the
first orally administered CGRP antagonist) has been
shown to possess efficacy similar to that of zolmitriptan
as acute therapy [59]. It also shows improved safety and
tolerability [60], although it caused elevated levels of
liver transaminases in a minority of patients taking the
drug twice daily for three months [61]. Insights gleaned
from genetic studies offer novel drug targets and poten-
tial prophylactic agents through alterations in neuronal
excitability. Indeed, current prophylactics such as
valproate, verapamil, topiramate and lamotrigine are
known to have effects on migraine-associated ion chan-
nels [62,63]. Several drugs that block glial cell activation
are also available and have approved clinical safety pro-
files. These drugs include naltrexone, naloxone, minocy-
cline and ibudilast, and some have already been shown
to be effective as prophylactics for migraine [24,64,65].
Summary and future directions
Migraine is a multigenic condition in which aberrant ion
channels are becoming increasingly implicated in patho-
genesis as inducing an altered state of peripheral and
central neuronal excitability. It is realistic to anticipate
that further genetic studies may reveal other tractable
drug targets, and this will help unravel the pathogenic
process in migraine, which is essential for the rational
development of effective treatments. Although each pro-
tein may be genetically relevant to only a small subset
of migraineurs, each one reveals important information
about migraine mechanisms potentially applicable to the
wider migraine population. It is likely that therapies
must be targeted against general pathways involved in
neuronal excitability, which will mean addressing both
neuronal and glial activation. Furthermore, it may be
crucial to understand the interplay of neurons and glia,
given that at least two FHM genes are of key impor-
tance for glial function. Indeed, simply targeting the
neuronal ion channels may be either partially or com-
pletely ineffective if glial adaptive changes circumvent
any therapeutic intervention. The use of triptans (and
soon likely CGRP antagonists) has made major leaps
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condition such as migraine, it may be that only thera-
pies targeting multiple pathways and cell types will lead
to drugs with broader and more sustained efficacy.
Equally true is that a better understanding of the genetic
architecture of migraine with the future availability of
rapid whole-genome sequencing in an individual could
lead to the ever sought after personalized medicine.
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